NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: TTKHLTCARE · data 2026-10-30
TTK Healthcare Limited
In plain words
Price: 27.4% below its 52-week high of ₹1,247.
Delivery: 52.7% of traded shares were kept for delivery over the last 10 sessions, against 53.3% over the last 60.
Latest results: a net profit of ₹223 cr for the quarter ended Sept 2026 (+993.5% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹888 cr |
| Net profit (last 12 months) | ₹74 cr |
| Sales growth, 3 years (yearly) | 5.7% |
| Profit growth, 3 years (yearly) | -53.2% |
Latest results in brief (Q2 FY27)
TTKHLTCARE Q2 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹233.38 crore, up 14.6% YoY and down 9.4% QoQ.
Net profit was ₹222.97 crore, up 993.5% YoY and up 947.8% QoQ.
Operating margin was 1.6% (2.6% a year ago).
EPS was ₹157.8, up 993.6% YoY and up 947.8% QoQ.
TTKHLTCARE के Q2 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹233.38 करोड़; पिछले साल की तुलना में 14.6% की बढ़त, पिछली तिमाही की तुलना में 9.4% की गिरावट।
शुद्ध मुनाफ़ा: ₹222.97 करोड़; पिछले साल की तुलना में 993.5% की बढ़त, पिछली तिमाही की तुलना में 947.8% की बढ़त।
ऑपरेटिंग मार्जिन: 1.6% (एक साल पहले 2.6%)।
EPS: ₹157.8; पिछले साल की तुलना में 993.6% की बढ़त, पिछली तिमाही की तुलना में 947.8% की बढ़त।
TTKHLTCAREના Q2 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹233.38 કરોડ; ગયા વર્ષની સરખામણીએ 14.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 9.4% ઘટાડો.
ચોખ્ખો નફો: ₹222.97 કરોડ; ગયા વર્ષની સરખામણીએ 993.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 947.8% વધારો.
ઓપરેટિંગ માર્જિન: 1.6% (એક વર્ષ પહેલાં 2.6%).
EPS: ₹157.8; ગયા વર્ષની સરખામણીએ 993.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 947.8% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 32.3% over the last 20 sessions vs 48.5% in the 40 before (0.67x); shares delivered per day 0.42x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 30 Oct 26Results Q2 FY27 results: profit +993.5% YoY
- 6 Aug 26Results Q1 FY27 results: profit +63.7% YoY +3.7% next session
- 17 Jul 26Dividend Dividend ₹10 (ex-date) +2.8% next session
- 30 May 26Results Q4 FY26 results: profit +34.7% YoY +2.7% next session
- 22 Jan 26Results Q3 FY26 results: profit −37.1% YoY -3.6% next session
- 17 Oct 25Results Q2 FY26 results: profit +18.5% YoY +3.8% next session
- 4 Aug 25Results Q1 FY26 results: profit −58.8% YoY -6.5% next session
- 18 Jul 25Dividend Dividend ₹10 (ex-date) -2.3% next session
- 23 May 25Results Q4 FY25 results: profit −11.6% YoY +1.4% next session
- 24 Jan 25Results Q3 FY25 results: profit +29.8% YoY -2.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹233 cr | ₹223 cr | +993.5% | 1.6% | 157.8 |
| Jun 2026 | ₹258 cr | ₹21 cr | +63.7% | 5.7% | 15.06 |
| Mar 2026 | ₹218 cr | ₹22 cr | +34.7% | 5.1% | 15.4 |
| Dec 2025 | ₹209 cr | ₹11 cr | -37.1% | 3.4% | 7.45 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 74.56% | 74.56% | 74.56% | 74.56% |
| Foreign institutions (FII) | 1.95% | 1.86% | 1.90% | 1.89% |
| Domestic institutions (DII) | 0.12% | 2.19% | 1.11% | 1.08% |
| Mutual funds | — | 0.00% | 0.00% | 0.00% |
| Retail investors | 13.39% | 12.05% | 12.90% | 12.89% |
| Number of shareholders | 23,993 | 22,809 | 23,686 | 22,481 |
Common questions
What was TTK Healthcare Limited's latest quarterly profit?
TTK Healthcare Limited reported a net profit of ₹223 cr for the quarter ended Sept 2026 (+993.5% on the same quarter a year earlier), on revenue of ₹233 cr.
How much do promoters hold in TTK Healthcare Limited?
Promoters held 74.56% of TTK Healthcare Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is TTK Healthcare Limited debt-free?
Its latest reported debt-to-equity ratio is 0.02, which is very low.
What is TTK Healthcare Limited's P/E ratio?
About 17.3, based on the last 12 months' earnings and a price of ₹905.3 (data 2026-10-30).
What is the 52-week high and low of TTK Healthcare Limited?
The 52-week high is ₹1,247 and the 52-week low is ₹735.
Similar companies
Venus Remedies Limited (VENUSREM) · NGL Fine-Chem Ltd. (NGLFINE) · Accent Microcell Limited (ACCENTMIC) · Anlon Healthcare Limited (AHCL) · Bharat Parenterals Ltd. (BPLPHARMA)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open TTKHLTCARE in NSE Scanner →